Table 3 |
|||
|
Treatment failures by Day 28 (adjusted by genotyping), stratified by age group |
|||
| Treatment groups |
No. of treatment failure/Total of Patients (%) [95% CI] |
||
|
|
|||
| Age groups |
Significance level P* |
||
|
|
|||
| 0.5 – 4 years |
≥ 5 years |
||
|
|
|||
| CQ |
69/131 (52.6) [44.1–61.1] |
63/169 (37.3) [30.2–44.7] |
0.01 |
| SP |
8/171 (4.7) [2.2–8.7] |
3/190 (1.6) [0.4–4.2] |
0.57 |
| AQ |
4/174 (2.3) [0.7–5.5] |
2/182 (1.1) [0.2–3.6] |
0.64 |
| ASAQ |
4/161 (2.8) [0.8–5.9] |
2/169 (1.2) [0.2–3.9] |
0.51 |
|
|
|||
|
CQ: Chloroquine; AQ: Amodiaquine; ASAQ: Artesunate + Amodiaquine; SP: Sulphadoxine-Pyrimethamine. CI: Confidence Interval Chi-square test for the comparison of two proportions |
|||
|
Ménard et al. Malaria Journal 2008 7:55 doi:10.1186/1475-2875-7-55 |
|||
